Tecan Shows Ongoing Commitment to Clinical and Research Markets in China
News Jun 24, 2013
The two-day program included a series of presentations and interactive workshops – as well as tours of Tecan’s research and manufacturing facilities in both Männedorf, Switzerland, and Grödig, Austria – and was intended to help guide the future development of Tecan laboratory automation solutions for this fast-growing market.
The visit began at Tecan’s global headquarters on the shores of Lake Zurich, with a presentation and demonstration of a Freedom EVO workstation configured for ELISA processing. This system, developed as part of an ongoing collaboration with hospitals and blood centers across China, introduces a number of unique features designed specifically to meet the requirements of the Chinese clinical market. The latest developments for this exciting project include a number of options to increase throughput and ease-of-use, such as a Chinese language version of the recently released TouchTools™ 3.0 touchscreen user interface. Sample and process security has been further enhanced with the addition of Tecan’s unique QC Kit, which provides liquid handling performance verification and reporting to comply with stringent regulations. Visitors were also given the opportunity to outline their current hospital laboratory practices and likely future requirements, helping to ensure that future clinical solutions are tailored to the exact needs of end-users.
The Austrian leg of the tour included presentation of a number of detection solutions to meet various aspects of clinical and research laboratory workflows, as well as interactive workshops to help shape future development of detection instruments and software for the Asian research market. Customers were introduced to a number of solutions from Tecan’s detection portfolio, including cost-effective instruments for routine ELISA processing – such as the Infinite F50 ELISA reader and Sunrise™ absorbance reader – and state-of-the-art multimode readers, such as the Infinite M1000 PRO. Delegates were given a demonstration of the Infinite M1000 PRO’s advanced assay development capabilities, combining premium Quad4 Monochromators™ optics with a range of advanced software features – such as luminescence scanning capabilities – to provide unlimited flexibility in assay design. The versatility of the Infinite M200 PRO was also highlighted during the visit, showcasing both the unrivalled cell-based assay performance of the system’s Gas Control Module (GCM™) and the low volume DNA quantification capabilities of Tecan’s unique NanoQuant Plate™. The trip was rounded off with a brief introduction to some of the vibrant history and culture of both Salzburg and Vienna, giving delegates a chance to take a mix of fond memories and innovative ideas back to their own laboratories.
New evidence published in the Cochrane Library provides high quality evidence that people who use a combination of nicotine replacement therapies (a patch plus a short acting form, such as gum or lozenge) are more likely to successfully quit smoking than people who use a single form of the medicine.READ MORE